NBY  Novabay Pharmaceuticals Inc.

Exchange

AMEX

Sector

Consumer Durables

Industry

Major Pharmaceuticals

Market Cap.

30.97M

Vuru Grade

23.16/100

Current Price

$0.42
+0.0193 (+4.8178%)

Stability Price

$0.30
Overvalued by 29.70%

Company Metrics

  • P/E 0
  • P/S 13.4976
  • P/B 5.9791
  • EPS -0.3280
  • Cash ROIC -2,078.99%
  • Cash Ratio 1.62
  • Dividend 0 / N/A %
  • Avg. Vol. 300,177.00
  • Shares 49.63M
  • Market Cap. 30.97M

Company Description

NovaBay Pharmaceuticals Inc., a clinical stage biotechnology company, engages in developing proprietary and patented topical Aganocide compounds for the treatment and prevention of various infections without causing bacterial resistance. Its Aganocide compounds are synthetic anti-infective product candidates with equivalent activity to the active antimicrobial molecules generated within white bloo... more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

NovaBay Pharmaceuticals Signs Distribution Agreement to Make Avenova Available ...
Benzinga - Sep 2, 2015
NovaBay┬« Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today announced that the company's breakthrough prescription ...
Company Shares of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) Drops by -8.86%
American Trade Journal - Aug 31, 2015
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) has lost 8.86% during the past week and dropped 37.96% in the last 4 weeks.
Worth Watching Stocks: Advanced Micro Devices, Inc. (NASDAQ:AMD), NovaBay ... - Stock Transcript
Short Interest Update on NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY)
Money Flow Index - Aug 13, 2015
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY), A reduction of 74,183 shares or 2.8% was observed in the short interest of NovaBay Pharmaceuticals The interest on July 31,2015 came in at 2,529,670 shares and as per the average daily trading of 101,905 ...
NovaBay Pharmaceuticals Reports 2015 Second Quarter Financial Results - Business Wire (press release)
NovaBay Pharmaceuticals (NBY) Announces Earnings Results, Meets Estimates - Dakota Financial News
Novabay Pharmaceuticals (NBY) Stock Spikes After FDA Approves Disinfection System
TheStreet.com - Jun 4, 2015
NEW YORK (TheStreet) -- Novabay Pharmaceuticals (NBY - Get Report) shares are up 11.46% to 93 cents per share in afternoon trading on Thursday after the biopharmaceutical company announced that it received clearance from the Food and Drug ...
FDA Clears NovaBay Pharmaceuticals' New High-Tech Device, intelli-Case, for ... - MarketWatch
Company Shares of NovaBay Pharmaceuticals, Inc. Drops by -3.92%
News Watch International - Aug 3, 2015
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) has lost 3.92% during the past week and dropped 10.74% in the last 4 weeks.
Shares of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) Drops by -29.08%
Insider Trading Report - Aug 23, 2015
NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) has lost 29.08% during the past week and dropped 34.6% in the last 4 weeks.
Company Shares of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) Rally 0.18%
American Trade Journal - Aug 17, 2015
Shares of NovaBay Pharmaceuticals, Inc. (NYSEMKT:NBY) appreciated by 0.18% during the past week but lost 14.96% on a 4-week basis.
NovaBay Pharmaceuticals Inc.: NovaBay Pharmaceuticals Reports 2015 Second ...
The Wall Street Transcript - Aug 16, 2015
NovaBay┬« Pharmaceuticals, Inc. (NYSE MKT: NBY), a biopharmaceutical company commercializing and developing topical non-antibiotic antimicrobial products for the global eye care market, today reported financial results for the three months and six ...
Maxim Group Remains Positive on Novabay Pharmaceuticals, Inc. (NBY) In Light ...
Smarter Analyst - Jun 5, 2015
A research report was issued today by Maxim Group analyst Jason Kolbert on Novabay Pharmaceuticals, Inc. (NYSE:NBY), after the company announced receipt of 510(k) clearance from the U.S.
Maxim Rates NovaBay At Buy, Says 'The Eyes Have It!'
Benzinga - Apr 30, 2015
In a report published Thursday, analysts at Maxim Group initiated coverage of NovaBay Pharmaceuticals, Inc. (NYSE: NBY) with a Buy rating and a price target of $2.